Kuros Biosciences AG (SWX:KURN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
25.62
+0.06 (0.23%)
Jan 30, 2026, 5:30 PM CET
13.36%
Market Cap1.00B +20.1%
Revenue (ttm)103.35M +129.8%
Net Income-6.07M
EPS-0.13
Shares Out39.15M
PE Ration/a
Forward PE108.79
Dividendn/a
Ex-Dividend Daten/a
Volume67,363
Average Volume191,783
Open25.50
Previous Close25.62
Day's Range25.48 - 25.96
52-Week Range14.00 - 34.20
Beta0.67
RSI38.95
Earnings DateMar 10, 2026

About Kuros Biosciences AG

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bon... [Read more]

Sector Healthcare
Founded 2016
Employees 158
Stock Exchange SIX Swiss Exchange
Ticker Symbol KURN
Full Company Profile

Financial Performance

In 2024, Kuros Biosciences AG's revenue was 75.56 million, an increase of 125.11% compared to the previous year's 33.56 million. Losses were -4.29 million, -68.75% less than in 2023.

Financial Statements

News

Kuros 9-month Revenue Up 77%; Raises 2025 Sales Guidance

(RTTNews) - Kuros Biosciences (KURN.SW) reported that, for the first nine months of 2025, total group revenue was $101.1 million, up by 77% compared with the same period in 2024. Revenue from Direct M...

3 months ago - Nasdaq